Talk:Burosumab

Changes to approvals of burosumab
I'm still figuring out how to add this myself, but in the meantime could the following be added:

The article says burosumab is indicated for XLH at age one and up, but it's since been expanded to six months and up. September 30, 2019 https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-and-kyowa-kirin-announce-us-fda-approves-label-update AuthorGinJones (talk) 23:22, 19 October 2020 (UTC)